Cytokine network in psoriasis. Cross-talk between keratinocytes and cells of the skin immune system

Central-European Journal of Immunology

Volumn 31, Issue 3-4, 2006, Pages 111-116

  Wojas Pelc, Anna ^a   Ciszek, Marta ^a   Kurnyta, Maria ^a   Marcinkiewicz, Janusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Inflammation; Keratinocytes; Proinflammatory cytokines; Psoriasis; Th1 lymphocytes

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LITHIUM; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BETA HEMOLYTIC STREPTOCOCCUS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFICACY; HEREDITY; HUMAN; KERATINOCYTE; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; UNSPECIFIED SIDE EFFECT;

EID: 34247595884     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. (2004): Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135: 1-8.
2. Krueger JG, Bowcock A (2005): Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2: 30-36.
3. Krueger G, Ellis CN (2005): Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53 (1 Suppl 1): S94-S100.
4. Henseler T, Christophers E (1985): Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13: 450-456.
5. Rahman P, Elder JT (2005): Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64: Suppl 2: ii37-ii39.
6. Majewski S, Jabłonska S (2003): Epidermodysplasia verruciformis human papillomaviruses in skin cancer and psoriasis. Przegl Dermatol 5: 327-333.
7. Fortune DG, Richards HL, Main CJ, et al. (1998): J Am Acad Dermatol 39: 196-201.
8. Tsankov N, Angelova I, Kazandjieva J (2000): Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 1: 159-165.
9. Higgins E (2000): Alcohol, smoking and psoriasis. Clin Exp Dermatol 25: 107-110.
10. Wardrop P, Weller R, Marais J, et al. (1998): Tonsillitis and chronic psoriasis. Clin Otolaryngol 23: 67-68.
11. Kormeili T, Lowe NJ, Yamauchi PS (2004): Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol 151: 3-15.
12. McFadden J, Valdimarsson H, Fry L (1991): Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol 125: 443-447.
13. Christophers E (2001): Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 26: 314-320.
14. Langley RG, Krueger GG, Griffiths CE (2005): Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64: ii18-ii23.
15. Elder LT, Klein SB, Tavakkol A, et al. (1990): Growth factor and proto-oncogene expression in psoriasis. J Invest Dermatol 95 (5 Suppl): 7S-9S.
16. Mascia F, Mariani V, Girolomoni G, et al. (2003): Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163: 303-312.
17. Peus D, Beyerle A, Vasa M, et al. (2004): Antipsoriatic drug anthralin induces EGF receptor phosphorylation in keratinocytes: requirement for H(2)O(2) generation. Exp Dermatol 13: 78-85.
18. Koo J, Khera P (2005): Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 38: 75-87.
19. Ellis CN, Krueger GG, Alefacept Clinical Study Group (2001): Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345: 248-255.
20. Albanesi C, Scarponi C, Giustizieri ML, et al. (2005): Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 4: 329-334.
21. Schaerli P, Britschgi M, Keller M, et al. (2004): Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 173: 2151-2158.
22. Wetzel A, Wetzig T, Haustein UF, et al. (2006): Increased neutrophil adherence in psoriasis: role of the human endothelial cell receptor Thy-1 (CD90). J Invest Dermatol 126: 441-452.
23. McGregor JM, Barker JN, Ross EL, et al. (1992): Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins. J Am Acad Dermatol 27: 383-388.
24. Yu Y, Tang L, Wang J, et al. (2002): Psoriatic lesional keratinocytes promote the maturation of human monocyte-derived Langerhans cells. Dermatology 204: 94-99.
25. Lowes MA, Chamian F, Abello MV, et al. (2005): Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci 102: 19057-19062.
26. Gottlieb AB, Chamian F, Masud S, et al. (2005): TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175: 2721-2729.
27. Pelle E, Mammone T, Maes D, et al. (2005): Keratinocytes act as a source of reactive oxygen species by transferring hydrogen peroxide to melanocytes. J Invest Dermatol 124: 793-797.
28. Jiang WY, Chattedee AD, Raychaudhuri SP, et al. (2001): Mast cell density and IL-18 expression in nonlesional and lesional psoriatic skin. In. J Dermatol 40: 699-703.
29. McInnes IB, Gracie JA (2004): Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 4: 392-397.
30. Schottelius AJ, Moldawer LL, Dinarello CA, et al. (2004): Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 13: 193-222.
31. Wittmann M, Purwar R, Hartmann C, et al. (2005): Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J Invest Dermatol 124: 1225-1233.
32. Langrish CL, Chen Y, Blumenschein WM, et al. (2005): IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
33. Piskin G, Sylva-Steenland RM, Bos JD, et al. (2006): In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176: 1908-1915.
34. Lee E, Trepicchio WL, Oestreicher JL, et al. (2004): Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130.
35. Fickenscher H, Hor S, Kupers H, et al. (2002): The interleukin-10 family of cytokines. Trends Immunol 23: 89-96.
36. Jung M, Sabat R, Kratzschmar J, et al. (2004): Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol 34: 481-493.
37. Wei CC, Chen WY, Wang YC, et al. (2005): Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol 117: 65-72.
38. Rich BE (2003): IL-20: a new target for the treatment of inflammatory skin disease. Expert Opin Ther Targets 7: 165-174.
39. Liao YC, Liang WG, Chen FW, et al. (2002): IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 169: 4288-4297.
40. Li HH, Lin YC, Chen PJ, et al. (2005): Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol 153: 591-595.
41. Boniface K, Bernard FX, Garcia M, et al. (2005): IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174: 3695-3702.
42. Hanselmann C, Mauch C, Werner S (2001): Haem oxygenase-1: a novel player in cutaneous wound repair and psoriasis? Biochem J 353: 459-466.
43. Lange RW, Hayden PJ, Chignell CF, et al. (1998): Anthralin stimulates keratinocyte-derived proinflammatory cytokines via generation of reactive oxygen species. Inflamm Res 47: 174-181.
44. Lebwohl M, Ting PT, Koo JY (2005): Psoriasis treatment: traditional therapy. Ann Rheum Dis 64 Suppl 2: ii83-ii86.
45. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. (2005): Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52: 2513-2518.
46. Wojas-Pelc A, Marcinkiewicz J (2006): What is a role of heme oxygenase-1 in psoriasis? Current concepts of pathogenesis. Int J Exp Pathol [in press].